Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Legend Biotech (LEGN – Research Report) today. The company’s shares ...
TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback